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of great importance to clinical cancer diagnosis is the use of organic biomarkers. The de-
tection of rNA, DNA, and protein antigen are all established methods for identifying specific
cancer types and instrumental in promoting greater survivorship of the patient. Despite many
decades of intense cancer research, we have yet to identify a “universal” protein or nucleic
acid that allows us to diagnose more than a small subset of cancers at a time. In this review,
we examine the use of localized cellular acidity as a universal marker for solid tumors, out-
lining some successes with a small peptide we call pHLIP, a pH-sensitive biosensor that al-
lows us to label tumor tissue in live mice.
One of the major forefronts in cancer re-
search is the use of biomarkers for cancer di-
agnosis. Many methods have been devised
in the last two decades to screen protein anti-
gen and nucleic acid markers known to be
specific to different tumor types [1]. Perhaps
the most successful in this line of biomarker
technologies has been the development of as-
says sensitive to changes in Her2/Neu ex-
pression,  the  aggressive  breast  tumor
proto-oncogene [2]. Protein and RNA ex-
pression assays have been in use clinically
for  some  time,  and  the  recent  advent  of
DNA-based techniques allows clinicians the
opportunity to monitor specific mutations
over time by tracking susceptible genes in
patients with established genetic risk [3]. Al-
though these methods are crucial for the early
detection of disease, they are all limited by
the fact that each method detects only one or,
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translocationat best, a minimal subset of cancer types. De-
spite more than a half century of intense can-
cer research, we still have not found a protein
or nucleic acid that functions as a “universal”
biomarker for all cancers.
Interestingly, there is a universal marker
for virtually all solid tumors often over-
looked and lost in the vast wealth of cancer
literature. This universal marker is localized
cellular acidity [4]. It has long been ob-
served that cancer tissues in vivo are more
acidic than normal tissues. This observation
is attributed to the effects of hypoxia and
called the Warburg effect [5] and from the
heightened  metabolic  activity  of  cancer
cells. A variety of conjectures and observa-
tions exist in the literature about how this lo-
calized acidity may facilitate certain cancer
traits such as longevity, growth, and metas-
tasis  [6,7,8].  Several  methods,  including
magnetic resonance imaging [9] and direct
in  vivo measurements  with  glass  probes
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Figure 1. A) pHLIP exists in three biophysical states depending on context: State I, as a
largely unstructured monomer in aqueous solution at slightly basic or neutral pH; State II, as
a largely unstructured monomer partitioned to the membrane surface in the presence of li-
posomes; and State III, as an inserted, bilayer-spanning ʱ-helix at low pH. All states are re-
versible as denoted by the double arrows. Adapted from Biophys J. 2007;93(7):2363-72 [17].
B) The primary sequence of pHLIP. red indicates hydrophobic residues, black indicates polar
residues, blue indicates acidic residues, and underlined green indicates basic residues. The
bracket denotes residues at positions 9-30 containing the two aspartic acids (blue D) at po-
sitions 14 and 25. The highlighted yellow residues comprise the cysteine tag attached to the
inserting end of the peptide for use in conjugating cargo molecules for translocation into cells.
C) The mechanism of pHLIP insertion at low pH: Insertion is largely dependent on the titra-
tion of the two aspartic acids (blue circles) at positions 14 and 25. Acidic protons (red circles)
bind to the basic aspartic side chains at low pH, neutralizing the charge and converting the
side chains into a more hydrophobic form. This thermodynamic conversion facilitates inser-
tion by lowering the energy barrier (by about 3 kcal/mol [13]) for stable interaction with the
membrane bilayer.[10], have been used in the last few decades
to confirm the observation. Despite a good
deal of information on the phenomenon, lit-
tle systematic effort has been devised until
recently to try to exploit this fundamental
characteristic for use as a cancer biomarker.
pHLIP AS A CAnCer BIoSenSor
On average, tumor tissues have been
found to be roughly a half pH unit more
acidic than their normal tissue counterparts
[4]. This observation has been made for both
mouse and human tumors and seems to be a
universal trait for all solid tumors examined
thus far in the literature. The degree of the
pH difference is, of course, variable de-
pending on tumor type with adenocarcino-
mas  typically  giving  the  largest  pH
differences [9,10], sometimes upwards of
0.7 to 0.8 pH units. Quite by accident, our
lab has discovered a small pH-sensitive pep-
tide called pHLIP† (pH-Low Insertion Pep-
tide) that seems to be sensitive enough to
detect these small pH differences in vivo, al-
lowing us to label areas of localized acidity
in mice.
pHLIP was first reported in 1997 [11]
when we were using bacteriorhodopsin to
study  the  two-stage  model  of  membrane
protein assembly [12]. At this time, our lab
was interested in testing the possibility that
the  cleaved  helices  of  bacteriorhodopsin
could spontaneously reassemble into a func-
tional protein in the presence of lipids. Dur-
ing this process, it was found that one of the
helices, the C3 helix, despite being quite hy-
drophobic, would not insert into membranes
unless the pH was reduced. This C3 helix is
the peptide we now call pHLIP (Figure 1).
Using a variety of biophysical methods,
including tryptophan fluorescence [13], cir-
cular  dichroism  [14],  and  Fourier-trans-
formed infrared spectroscopy [11], our lab
has extensively characterized the behavior
of pHLIP in synthetic liposomes to deter-
mine that pHLIP exists in three different bio-
physical states depending on environmental
context (Figure 1A). These three states are
as follows: 1) in the absence of lipids and at
neutral or slightly basic pH, pHLIP exists as
a relatively unstructured monomer in aque-
ous  solution;  2)  in  the  presence  of  lipid
membranes at neutral or slightly basic pH,
unstructured pHLIP partitions very favor-
ably to the membrane surface; and 3) at low
pH, pHLIP inserts spontaneously (and re-
versibly) into the membrane as a spanning
ʱ-helix. It is this latter insertion and the tran-
sition between states 2 and 3 that allows us
to use pHLIP as a pH-sensitive biosensor.
This is because local acidic milieu in vivo is
enough to trigger the pH-dependent inser-
tion of pHLIP (Figure 1C), allowing the pep-
tide  to  insert  and  be  retained  in  the
membranes of cells found in areas of local-
ized acidity.
pHLIP In vIvo LABeLIng
By covalently attaching fluorophore mol-
ecules to the N-terminal, non-inserting end of
pHLIP, in a collaboration with groups at the
University of Rhode Island, we have been
able to intravenously and peritoneally inject
pHLIP-fluorophore conjugates into live mice
harboring human tumors and observe prefer-
ential retention of the construct in cancerous
tissue (Figure 2A-B) [15]. This retention was
very pronounced for a variety of tumor sizes
[15], even 5 days after an initial implantation
of only 105 cancer cells subcutaneously in
nude mice. As mentioned above, we attribute
this retention to the well-characterized pH-de-
pendent insertion of the peptide: The peptide
senses localized acidity and responds by in-
serting into cell membranes as a spanning ʱ-
helix, anchoring the fluorophore in place.
The kinetics of pHLIP localization are
such that most of the conjugate clears from
mice within 24 hours (Figure 2C), leaving
an obvious retention in the tumor that per-
sists for more than a week (Figure 2D). Al-
though we have not yet performed in-depth
toxicology on the mice used in these stud-
ies,  careful  monitoring  of  the  animals
showed that the conjugates resulted in no
obvious adverse physiological or behavioral
side effects. As far as we could detect, the
conjugates seemed to label the entirety of
the tumors with no adjacent tissue being la-
beled at all [21].
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hibit  some  off-site  localization  [15]. The
most  prominent  off-site  localization  was
found in the kidneys (Figure 2A-B), where
the proximal tubule region is particularly
well labeled (Figure 2E). This labeling is
consistent with the fact that our conjugates
are  small  enough  to  enter  through  the
glomerular fenestrae and be treated as fil-
trate. Since the proximal tubules of the kid-
neys are acidified to drive sodium ions across
the membrane, our conjugates are likely re-
sponding to this acidity, inserting into kidney
cells and being retained in the tubule tissue.
We do not know exactly in what part of the
cells this retention occurs, but we did find
that feeding the mice carbonated water helps
to alleviate kidney labeling (Figure 2E) with-
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Figure 2. Intravenously and intraperitoneally injected pHLIP-infrared dye conjugates localize
preferentially to tumors. A) overlay of NIr fluorescence and X-ray images obtained the day
after injection of 500ﾵg/kg pHLIP-cy5.5 conjugate (right) or an equivalent amount of free cy5.5
(left) into mice bearing tumors in the right flank. Peptide injection was performed on the sixth day
after an initial cancer-cell implantation of 5x104 cells subcutaneously. Localization of the fluo-
rophore is seen in the tumor, kidneys, and spleen. B) pHLIP-Alexa750 fluorescence (green) in
a mouse bearing a tumor in the right flank (6 days after 106 cell implant) imaged the day after
peptide injection. reflectance is denoted in red. Localization of the fluorophore is seen in the
tumor (arrow), kidneys, and spleen. C) pHLIP-cy5.5 given as a single injection (200ﾵg/kg) into
the left side of mice initially diffuses, accumulating in the right flank tumor by 20 hours. Blue
represents background and red represents the highest fluorescence. D) 3D representations of
pHLIP-cy5.5 fluorescence from a tumor-bearing mouse at different days after injection of
500ﾵg/kg peptide. Peptide injection was done on the seventh day after subcutaneous tumor im-
plantation. The height (z axis) and intensity of red indicates the strength of NIr signal, showing
that pHLIP retention lasts for several days. e) The NIr fluorescence of kidneys 2 days after in-
jection of 500ﾵg/kg pHLIP-Alexa750 into mice fed water (left) or 80 mm NaHco3 at pH 8.2
(right). The alkaline treatment resulted in an approximate 50 percent reduction of pHLIP kidney
retention without affecting tumor localization. Figures reprinted from [15]: Andreev oA, et al. mecha-
nism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc Natl Acad
Sci USA. 2007;104(19):7893-8, reused according to permissions guidelines.out changing tumor labeling, in agreement
with the interpretation.
pHLIP’s InSertIon MeCHAnISM
The mechanism of pHLIP’s pH-depen-
dent insertion intimately involves the side
chain topology of the peptide [11,17]. pHLIP
is a hydrophobic peptide with a long stretch
of hydrophobic residues from positions 9 to
30 (Figure 1B). From a number of experi-
ments, we have determined that pHLIP’s pH-
dependence is largely due to the titration of
the two aspartic residues at positions 14 and
25. When acid is added, these two residues
become protonated, converting from charged
forms to polar, uncharged forms. This proto-
nation effectively converts each residue into
a more hydrophobic form, facilitating and
stabilizing peptide insertion thermodynami-
cally (Figure 1C), with the two aspartates
likely participating directly in spanning the
membrane. In addition to the two aspartic
residues in the spanning domain, it is likely
the three charged residues at the C-terminal,
inserting end of the peptide (Figure 1B) and
the free carboxyl at the C-terminus also need




One of the implications of the insertion
process is that the C-terminal (inserting end)
of the peptide makes contact with the other
side of the bilayer after insertion (Figure
1C). We were interested to see if this translo-
cation of the C-terminal could be used to
translocate cargo molecules from one side
of the membrane bilayer to the other. By
adding a cysteine residue to the C-terminus,
we have, in fact, been able to attach mole-
cules such as dansyl dye and PNAs by disul-
fide bonding or bonds and translocate them
across synthetic liposome bilayers and cell
plasma  membranes  [14].  Since  disulfide
bonds are cleaved when they make contact
with the highly reducing environment of the
cytosol, our pHLIP-conjugate platform of-
fers a cleavable, releasable cargo transloca-
tion that results in retention of cargo mole-
cules in cells even after the peptide has been
washed away (Figure 3A-B) [14]. This plat-
form has been used to translocate phalloidin
toxin into cells and stimulate cell death in
culture (Figure 3C-D) [19], a very direct
demonstration of the high potential pHLIP
has for use in translocating and targeting
drug molecules to tumor tissues.
SIgnIFICAnCe AnD oUtLook
In addition to solid tumors, areas of in-
flammation such as arthritis also have been
shown to exhibit a locally restricted acidic
milieu [16]. To see if pHLIP could be used
as a probe for these other areas of localized
acidity, pHLIP conjugates were tested in a
rat arthritis model [15], where inflammation
was induced using a solution of Freud’s ad-
juvant and BSA injected into the rat’s knee.
Much to our satisfaction, we found pHLIP-
fluorophore conjugates preferentially local-
ized to the areas of induced inflammation
with  similar  kinetics  as  for  tumors  [15],
opening the door for pHLIP’s use in a wider
range of diagnostic and drug-delivery appli-
cations.
We have reviewed here some of the key
characteristics  and  properties  of  pHLIP,
which uses acidity as a marker for disease
tissue. Not only does pHLIP allow for spe-
cific localization of fluorophores to tumors
and sites of inflammation, but it also offers
immense potential as a translocation and
drug delivery platform. The obvious nonin-
vasive nature of the technology is a key at-
traction,  along  with  the  fact  that  pHLIP
appears to be benign even when injected into
mice in moderate quantities. Unlike most
other diagnostic methods dependent on spe-
cific protein antigens such as CA-2 (prostate
cancer) or CA-125 (ovarian cancer), pHLIP
offers the potential for use as a broader-spec-
trum diagnostic tool that does not simply
identify proteins specific to a limited subset
of cancer types but actually localizes in vivo
to the site of the tumor, giving pHLIP power
in not only diagnosing the presence of solid
tumors but also in labeling their location and
size. We expect our ongoing efforts in con-
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raphy (PET) [20] and MRI probes to further
develop this technology.
It should be noted that the pHLIP tech-
nology is still in its infancy. We have thus
far only demonstrated proof-of-principle ap-
plications. We have not yet conducted any
head-to-head  comparisons  with  existing
cancer diagnostic techniques to determine
relative efficacy, nor have we performed an
exhaustive labeling survey of more than a
few tumor types. We are also aware of the
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Figure 3. pHLIP can translocate cargo molecules across a lipid bilayer at low pH. A) HeLa cells
were incubated for 15 minutes with 7 ﾵm cleavable pHLIP-S-S-dansyl at extracellular pH of 5.5,
6.5, 7.0, or 7.4, followed by many pH 7.4 PBS washes to remove inserted peptide. The ob-
served fluorescence is from the dansyl dye retained in the cells after disulfide cleavage and
peptide removal. pH treatment values more acidic than the typical pH of an in vivo solid tumor
were used to accelerate the translocation process. B) Quantification of the retained dye fluo-
rescence in (A). The signal from cells at pH 5.5 was taken as 100 percent. Dye retention strongly
decreases with an increase in extracellular pH. C) HeLa cell growth is strongly inhibited with in-
cubation of increasing concentrations of a cleavable pHLIP-S-S-phalloidin construct at low ex-
tracellular pH. HeLa cells were incubated with 1, 2, or 4 ʼm pHLIP-S-S-phalloidin for 3 hours at
pH 6.2 (black bars) or 7.4 (gray). After 4 days growth, the number of remaining viable cells was
determined using the Promega AQueous one assay. All readings are normalized to a 0 ʼm
peptide, pH 7.4 control. Errors of the mean were estimated using the two-tailed Student t dis-
tribution. D) Same experiment as in (c) using m4A4 cells instead of HeLa. relabeled figures
reprinted according to permissions guidelines: A-c: reshetnyak YK, et al. Translocation of molecules into
cells by pH-dependent insertion of a transmembrane helix. Proc Natl Acad Sci USA. 2006;103(17):6460-5
[14]; D: An m, et al. pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin
toxin inhibits cancer cell proliferation. Proc Natl Acad Sci USA. 2010;107(47):20246-50 [19].possibility of false-positives for cancer de-
tection, particularly in older patients with
chronic inflammatory disorders. Neverthe-
less, pHLIP shows great promise as a diag-
nostic tool, and we hope continuing work
will yield new interest and ideas in the use of
pH as a universal biomarker for cancer.
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